Pure Global

Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia - Trial NCT05682807

Access comprehensive clinical trial information for NCT05682807 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05682807
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05682807
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia
Caffeine Versus Probiotic as Adjuvant Therapy for Preterm Neonates With Bronchopulmonary Dysplasia

Study Focus

Caffeine

Interventional

drug

Sponsor & Location

Tanta University

Tanta, Egypt

Timeline & Enrollment

Phase 3

Jun 30, 2022

Jun 01, 2025

90 participants

Primary Outcome

Complete blood count,Kidney function test,Liver function test,Inflammatory parameter

Summary

The aim of this study is to evaluate the effectiveness of caffeine versus probiotics
 supplementation as adjuvant therapy for preterm neonates with Bronchopulmonary dysplasia
 (BPD).

ICD-10 Classifications

Bronchopulmonary dysplasia originating in the perinatal period
Congenital bronchomalacia
Bronchopneumonia, unspecified
Other congenital malformations of bronchus
Diseases of bronchus, not elsewhere classified

Data Source

ClinicalTrials.gov

NCT05682807

Non-Device Trial